Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/22747
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSteward, WP-
dc.date.accessioned2012-10-24T09:11:45Z-
dc.date.available2012-10-24T09:11:45Z-
dc.date.issued1999-5-1-
dc.identifier.citationCANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43, pp. S56-S60-
dc.identifier.issn0344-5704-
dc.identifier.urihttp://hdl.handle.net/2381/22747-
dc.formatmetadata-
dc.language.isoEnglish-
dc.publisherSPRINGER VERLAG-
dc.sourceWeb of Science-
dc.source.urihttp://webofknowledge.com-
dc.subjectScience & Technology-
dc.subjectLife Sciences & Biomedicine-
dc.subjectOncology-
dc.subjectPharmacology & Pharmacy-
dc.subjectmarimastat-
dc.subjectclinical development-
dc.subjectBB2516-
dc.subjectMETALLOPROTEINASE INHIBITOR BATIMASTAT-
dc.subjectMATRIX METALLOPROTEINASES-
dc.subjectMETASTASIS-
dc.subjectCANCER-
dc.subjectCARCINOMA-
dc.subjectINVASION-
dc.subjectCELLS-
dc.subjectBB-94-
dc.subjectMICE-
dc.titleMarimastat (BB2516): Current status of development-
dc.typeJournal Article-
dc.identifier.doi10.1007/s002800051099-
dc.description.irispid73552-
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.